Approved Treatments for Muscular Dystrophy

There is no cure for any type of muscular dystrophy (MD), but various medications and therapies can help manage symptoms or slow the progression of the disease. Many therapies are specific to one type of dystrophy. Some of the treatments approved to treat MD are summarized below.


Patients with MD are often prescribed corticosteroids, also called glucocorticoids, which may preserve muscle tissue by reducing both inflammation and immune system attacks on those tissues. They also may speed up the processes that are involved in repairing cell membranes. There are many types of corticosteroids that may be prescribed for MD.


Emflaza (deflazacort) is a therapy to treat Duchenne muscular dystrophy (DMD) in patients 2 or older, regardless of disease-causing genetic mutation. Emflaza is a pro-drug, meaning that the therapy must be metabolized in the body into its active form. It contains a pro-corticosteroid, which, once metabolized, becomes a corticosteroid. Once metabolized to its active form, Emflaza acts to suppress the immune system.

Learn more


Prednisone is a synthetic corticosteroid that is generally prescribed to delay the progression of muscle weakness in muscular dystrophy patients. It mimics the action of a naturally occurring corticosteroid called cortisol, which is produced by the adrenal glands. Prednisone is prescribed for its anti-inflammatory properties, and in the case of MD, its long-term use can delay the progression of muscle weakness.

Learn more

Exon-skipping Therapies

Exon skipping is a treatment approach for people whose Duchenne muscular dystrophy is due to certain mutations in its causative gene. Exon skipping works like a molecular patch, so that the DMD gene can produce a shorter version of the dystrophin protein to help protect and maintain the strength of muscle fibers.

Amondys 45

Amondys 45 (casimersen) is a treatment for DMD patients with mutations amenable to exon 45 skipping. It is the third Sarepta exon-skipping therapy that the FDA approved for DMD patients. Others include Exondys 51 (eteplirsen) for patients amenable to exon 51 skipping and Vyondys 53 (golodirsen) for those with mutations amenable to exon 53 skipping.

Learn more

Exondys 51

Exondys 51 (eteplirsen or AVI-4658) is the first treatment approved by the FDA for a specific group of patients with DMD. These patients — 13% of the total Duchenne population — have gene deletions that are amenable to exon 51 skipping. Exondys 51 is designed to address the underlying cause of DMD.

Learn more


Viltepso (viltolarsen) is an approved therapy to treat DMD resulting from mutations amenable to exon 53 skipping. Viltepso is administered as an infusion into the bloodstream. Patients can choose to receive the weekly hour-long treatment, done by a healthcare professional, at home, at a hospital, or a treatment center. The FDA gave Viltepso conditional approval on Aug. 12, 2020. This conditional approval is pending the results of the ongoing Phase 3 RACER53 trial.

Learn more

Vyondys 53

Vyondys 53 (golodirsen, SRP-4053) is an approved exon-skipping therapy to treat DMD patients whose disease is amenable to exon 53 skipping. The FDA gave Vyondys 53 accelerated approval in December of 2019. Vyondys 53 is designed to mask exon 53 in the mRNA (a temporary copy of a gene used to make a protein) of the DMD gene so the protein synthesis machinery can skip this exon and piece together the remaining exons to make a smaller, but functional, dystrophin protein.

Learn more
Books icon

Your MD Community

Visit the Muscular Dystrophy News Today forums to connect with others in the muscular dystrophy community. These forums are designed for patients, caregivers, and medical professionals to discuss issues, ask questions, and share experiences.

View All Forums
Speech bubble icon